Skip to Main Content

Author Details

Fiona Blackhall
The University of Manchester
2000
232
60
PMIDPaper TitleJournal TitlePublished Year
36283797Respiratory distress symptom intervention for non-pharmacological management of the lung cancer breathlessness-cough-fatigue symptom cluster: randomised controlled trial.BMJ Support Palliat Care2024
36689692Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.J Clin Oncol2023
37861218Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.N Engl J Med2023
37748077A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells.Proc Natl Acad Sci U S A2023
37479829Plasticity of circulating tumor cells in small cell lung cancer.Sci Rep2023
37455012Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.J Thorac Oncol2023
37146348Support and information needs for patients with non-small cell lung cancer receiving concurrent chemo-radiotherapy treatment with curative intent: Findings from a qualitative study.Eur J Oncol Nurs2023
37142383REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.Lancet Oncol2023
37140730Patient and clinician-reported experiences of using electronic patient reported outcome measures (ePROMs) as part of routine cancer care.J Patient Rep Outcomes2023
37071029Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer.JCO Clin Cancer Inform2023
37355629Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.J Hematol Oncol2023
36746549Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.BMJ Open2023
35176458ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.Ann Oncol2022
35489288Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.ESMO Open2022
35781861Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.Target Oncol2022
35941262cfDNA methylome profiling for detection and subtyping of small cell lung cancers.Nat Cancer2022
35990583Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.EClinicalMedicine2022
36223028The Role of Electronic Patient-Reported Outcome Measures in Assessing Smoking Status and Cessation for Patients with Lung Cancer.Oncol Ther2022
32966755Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.Am J Respir Crit Care Med2021
33545577Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.Lung Cancer2021
33516147A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study.ESMO Open2021
33693944Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.J Clin Endocrinol Metab2021
33748440Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer.Clin Transl Radiat Oncol2021
33607312Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.J Thorac Oncol2021
34789728Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.Nat Commun2021
34758330TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.Cell Rep2021
34489586Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.Br J Cancer2021
34012782EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer.Transl Lung Cancer Res2021
34266853Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial).BMJ Open Respir Res2021
33957222Reframing recalcitrance for small-cell lung cancer.Ann Oncol2021
34033159Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital.Cytopathology2021
33466360Mechanisms of Resistance to KRAS<sup>G12C</sup> Inhibitors.Cancers (Basel)2021
32915318Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.Cancer Immunol Immunother2021
31629061Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC.J Thorac Oncol2020
35121965A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.Nat Cancer2020
31906892A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.BMC Cancer2020
33287165Liquid Biopsy in Small Cell Lung Cancer-A Route to Improved Clinical Care?Cells2020
33221678Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.Lung Cancer2020
32581069ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.ESMO Open2020
32721553The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.J Thorac Oncol2020
32445987Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.Radiother Oncol2020
32240795Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts.Ann Oncol2020
32485661Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.Lung Cancer2020
32483644Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform.Eur Radiol2020
32558295Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.EMBO Mol Med2020
31292268Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.Oncologist2020
30391573Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.J Thorac Oncol2019
31810511Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].Radiother Oncol2019
29999214Developing and testing a web-based intervention to encourage early help-seeking in people with symptoms associated with lung cancer.Br J Health Psychol2019
31239544Direct Ras G12C inhibitors: crossing the rubicon.Br J Cancer2019
  • 1 - 50 of 232

Recommended Authors

Zorawar S Noor
David Geffen School of Medicine at university of california los angeles
Career Start Year 2016
Number of shared co-authors 0
Philip E Lammers
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 2
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year 2012
Number of shared co-authors 2
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 6
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 3
Sara Kuruvilla
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2010
Number of shared co-authors 4
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 5
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 3
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 11
Puey Ling Chia
Lee Kong Chian School of Medicine, Nanyang Technological University
Career Start Year 2009
Number of shared co-authors 5
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 12
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 2
Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 11
Matthew A Gubens
University of California san francisco
Career Start Year 2003
Number of shared co-authors 5
Aaron Lisberg
Jonsson Comprehensive Cancer Center, university of california los angeles
Career Start Year 2002
Number of shared co-authors 2
Daniel Morgensztern
Washington University School of Medicine
Career Start Year 2000
Number of shared co-authors 10
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 4
Prudence A Russell
St Vincent's Hospital
Career Start Year 1997
Number of shared co-authors 9
Puneeth Iyengar
UT Southwestern Medical Center, Center for Human Nutrition
Career Start Year 1996
Number of shared co-authors 4
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 5
Jorge Nieva
Norris Comprehensive Cancer Center, University of Southern California
Career Start Year 1995
Number of shared co-authors 3
Cheryl Ho
University of British Columbia
Career Start Year 1995
Number of shared co-authors 6
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 14
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 10
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 9
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 8
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 8
David M Jablons
University of California, USA Cardiovascular Research Institute san francisco
Career Start Year 1981
Number of shared co-authors 6
Hira Rizvi
Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Career Start Year 1978
Number of shared co-authors 6

Collaborators

Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Co-authored papers 12
Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 11
Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers 8
Pasi A J??nne
Dana-Farber Cancer Institute
Co-authored papers 6
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 6
Dean A Fennell
University of Leicester
Co-authored papers 6
Dirk De Ruysscher
Maastro Clinic
Co-authored papers 6
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 5
Esther G C Troost
German Cancer Research Center (DKFZ)
Co-authored papers 4
Charles Swanton
Francis Crick Institute
Co-authored papers 4
Igor Jurisica
Schroeder Arthritis Institute
Co-authored papers 4
John Le Quesne
Beatson Cancer Research Institute, University of Glasgow
Co-authored papers 4
David A Moore
University College London Cancer Institute
Co-authored papers 4
Michael R Johnston
Dalhousie University
Co-authored papers 4
Shaf Keshavjee
University Health Network, University Health Network and University of Toronto
Co-authored papers 3
Lecia V Sequist
Massachusetts General Hospital Cancer Center, Harvard Medical School
Co-authored papers 3
Stephanie Peeters
University of Liege, Centre Hospitalier Universitaire de Liege
Co-authored papers 3
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Roberta Ferraldeschi
Astex Pharmaceuticals
Co-authored papers 3
Apostolos Nakas
University Hospitals of Leicester NHS Trust
Co-authored papers 3
Peter Van Loo
The Francis Crick Institute
Co-authored papers 3
Anthony D Whetton
Co-authored papers 3
Paul Wheatley-Price
The Ottawa Hospital Research Institute
Co-authored papers 3
Joakim Lundeberg
KTH Royal Institute of Technology
Co-authored papers 2
Chang-Qi Zhu
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
James Hicks
Michelson Center for Convergent Bioscience, University of Southern California
Co-authored papers 2
Terrie Cowley
Co-authored papers 2
Peter Kuhn
University of Tubingen
Co-authored papers 2
Davina Lau
Samuel Lunenfeld Research Institute/Mount Sinai Hospital
Co-authored papers 2
Release 1.2